DOTA-TOC Acetate is used for labeling with radionuclides to target somatostatin receptor-positive tumors. Once labeled, it binds to somatostatin receptors, which are overexpressed in neuroendocrine tumors, allowing for imaging (PET/SPECT) or peptide receptor radionuclide therapy (PRRT). The directory classifies it as a commercial API with a peptide source/manufacturing origin. Other names for this substance include DOTA-Tyr³-Octreotide Acetate. It is also listed for alternate use as: API Intermediate.
DOTA-TOC Acetate
| CAS No | 225037-12-9 |
|---|---|
| Molecular Formula | C₆₂H₈₇N₁₃O₁₉S |
| Molecular Weight | ~1385.5 g/mol |
| Synonyms | Acetate salt of DOTA-conjugated Tyr³-octreotide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
DOTA-TOC Acetate is used for labeling with radionuclides to target somatostatin receptor-positive tumors. Once labeled, it binds to somatostatin receptors, which are overexpressed in neuroendocrine tumors, allowing for imaging (PET/SPECT) or peptide receptor radionuclide therapy (PRRT).
The listed CAS number is 225037-12-9.
The listed molecular formula is C₆₂H₈₇N₁₃O₁₉S.
The listed molecular weight is ~1385.5 g/mol.
Acetate salt of DOTA-conjugated Tyr³-octreotide.
The source lists DOTA-Tyr³-Octreotide Acetate.